{"denoms":[{"counts":[{"groupId":"BG000","value":"363"},{"groupId":"BG001","value":"351"},{"groupId":"BG002","value":"714"}],"units":"Participants"}],"groups":[{"description":"Neoadjuvant treatment: Participants received 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles (up to 6 weeks) prior to surgery.\n\nAdjuvant treatment: Following surgical resection, participants received 200 mg pembrolizumab, IV infusion, on Day 1 of a 21-day cycle for 15 cycles (up to 45 weeks) plus investigator's choice of SOC treatment regimen consisting of radiotherapy, with or without cisplatin 100 mg/m\\^2, IV infusion, on Day 1 of a 21-day cycle for 3 cycles (up to 9 weeks).","id":"BG000","title":"Pembrolizumab + Standard of Care (SOC)"},{"description":"Adjuvant treatment: Following surgical resection, participants received investigator's choice of SOC treatment regimen consisting of radiotherapy, with or without cisplatin 100 mg/m\\^2, IV infusion, on Day 1 of a 21-day cycle for 3 cycles (up to 9 weeks).","id":"BG001","title":"Standard of Care (SOC)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.0","value":"59.4"},{"groupId":"BG001","spread":"10.0","value":"60.6"},{"groupId":"BG002","spread":"10.0","value":"59.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"151"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"277"},{"groupId":"BG002","value":"563"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"101"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"300"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"598"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"95"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"284"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"554"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"29"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"73"}],"title":"Oropharynx"},{"measurements":[{"groupId":"BG000","value":"219"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"432"}],"title":"Oral Cavity"},{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"154"}],"title":"Larynx"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"54"}],"title":"Hypopharynx"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Missing"}]}],"description":"The primary tumor site was categorized as tumor in oropharynx, oral cavity, larynx, and hypopharynx. The number of participants with tumor at each site at baseline was presented.","paramType":"COUNT_OF_PARTICIPANTS","title":"Primary Tumor Site","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"183"}],"title":"III"},{"measurements":[{"groupId":"BG000","value":"271"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"528"}],"title":"IVA"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"IVB"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Missing"}]}],"description":"American Joint Committee on Cancer 8th edition TNM stratified (PT=primary tumor \\[size \\& invasion of nearby tissue\\], LN=cancerous lymph nodes, Met=distant metastasis). Tumor site stages III: PT (fixated/limited invasion;\\>2-≥4cm+depth of invasion (DOI) \\>10mm/\\>4cm+DOI≥10mm); ipsilateral LN ≤3cm extranodal extension negative(ENE-) (except human papilloma virus \\[HPV\\]16+ oropharynx: invasive PT or LN\\>6cm); IVA: PT (moderate invasion-to adjacent structures\\[AS\\]);bilateral/ipsilateral/contralateral LN≤6cm ENE-; IVB: PT (advanced invasion-beyond AS) or LN\\>6cm ENE±. Higher numbers=more advanced cancer.","paramType":"COUNT_OF_PARTICIPANTS","title":"Overall Cancer Staging at Baseline","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"257"},{"groupId":"BG001","value":"242"},{"groupId":"BG002","value":"499"}],"title":"TPS <50%"},{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"210"}],"title":"TPS ≥50%"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Missing"}]}],"description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry (IHC) assay using tumor tissue from a newly obtained biopsy. The number of participants with TPS \\<50 and TPS ≥50 at baseline was presented. Higher percentages of PD-L1 TPS staining correspond to higher positivity of PD-L1 on a tumor.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death Ligand 1 (PD-L1) Status by Tumor Proportion Score (TPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"244"}],"title":"CPS <10"},{"measurements":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"231"},{"groupId":"BG002","value":"465"}],"title":"CPS ≥10"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Missing"}]}],"description":"The PD-L1 CPS status indicates tumor PD-L1 positivity using both tumor cells and inflammatory cells that are positive for PD-L1 by IHC. The number of participants with CPS \\<10 and CPS ≥10 at baseline was presented. Participants with a CPS \\<10 were classified as PD-L1 negative and participants with a CPS ≥10 were classified as PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Status by Combined Positive Score (CPS; CPS10)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"27"}],"title":"CPS <1"},{"measurements":[{"groupId":"BG000","value":"347"},{"groupId":"BG001","value":"335"},{"groupId":"BG002","value":"682"}],"title":"CPS ≥1"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Missing"}]}],"description":"The PD-L1 CPS status indicates tumor PD-L1 positivity using both tumor cells and inflammatory cells that are positive for PD-L1 by IHC. The number of participants with CPS \\<1 and CPS ≥1 at baseline was presented. Participants with a CPS \\<1 were classified as PD-L1 negative and participants with a CPS ≥1 were classified as PD-L1 positive.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Status by CPS (CPS1)","unitOfMeasure":"Participants"}]}